One World Cannabis Signed a Collaboration Agreement with Sheba Academic Medical Center

PETACH TIKVA, Israel, March 11, 2015 /PRNewswire/ --

OWC Pharmaceutical Research Corp.'s (OTCQB: OWCP) wholly owned subsidiary One World Cannabis Ltd. ("the Company"), signed a collaboration agreement with Sheba Academic Medical Center, the largest hospital in Israel and in the Middle East.

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )

Within the framework of a new collaboration agreement, the company will initiate a study to explore the effect of several combinations of cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma, starting with a basic science on multiple myeloma cells.

Multiple myeloma, a cancer of plasma cells, accounts for 10% of all hematologic malignancies. It is the second most common hematologic cancer and represents 1% of all cancer diagnoses and 2% of all cancer deaths.

The study will be conducted at the Sheba Academic Medical Center facilities, composed of a highly diverse yet interactive collaborative team of molecular biologists, immunologists, cell biologists and clinicians, located in Ramat Gan (near Tel Aviv), Israel.

Dr. Merav Leiba, Head of Multiple Myeloma outpatient clinic and Multiple Myeloma research lab at Sheba Academic Medical Center's hematology institute, will lead the research. Dr. Leiba, a specialist in Internal Medicine and Hematology, was a postdoctoral fellow at the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute, Boston, Massachusetts (2006-2008). Dr. Leiba has participated in numerous clinical and investigational studies aimed at developing novel drugs for multiple myeloma.

Dr. Alan Shackelford, the company's Chief Science Officer, will oversee this clinical research. Dr. Shackelford is a Harvard Medical School-trained physician with expertise in internal medicine, nutritional medicine, and behavioral medicine, and was also a Research Fellow at the Harvard Medical School. Dr. Shackelford has more than 30 years of clinical experience and is recognized as one of the leading authorities in the emerging field of cannabinoid medicine.

The company has recently received Sheba Academic Medical Center internal review board (IRB) approval to the study. This Helsinki Committee approval confirms that the medical trial does not contradict the principles of the Helsinki Declaration, the Israeli Public Health Regulations (Medical trials on humans) 5741-1980 and the Israeli Medical Trials on Humans Procedure, 2014.

Commenting on the collaboration, Ziv Turner, the company's Chief Executive Officer, said: "We are very pleased to be working with a highly regarded academic-based medical facility, and in compliance with international regulatory protocols. This collaboration supports the company's goal to be in the forefront of research and development of cannabis-based treatments for diseases and medical conditions."

About Sheba Academic Medical Center 

The Chaim Sheba Academic Medical Center at Tel Hashomer, Israel (near Tel Aviv), is the largest and the most comprehensive medical center in Israel and the Middle East, recognized internationally for its leadership in clinical treatment, as well as basic and applied medical research. It is situated on a 150-acre campus at Tel Hashomer on the outskirts of Tel Aviv. It is the teaching center for Tel Aviv University's medical and nursing schools, and is home to Israel's national institutes of health, central blood bank, and military rehabilitation facilities.

About One World Cannabis Ltd. 

One World Cannabis Ltd. ("the Company") is an Israel-based company founded in 2014 by a group of professionals with expertise in the field of medical cannabis (marijuana) treatment and medical cannabis regulatory affairs. The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB: OWCP).

Notice Regarding Forward-Looking Statements 

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Ziv Turner, CEO
One World Cannabis Ltd. (OWC)
http://www.OWCpharma.com
Tel: +972(0)54-5500450
Email: [email protected]

SOURCE One World Cannabis Ltd. (OWC)